高剂量布普伦诺芬启动:一个范围审查
Stanley Wong1, Nicholas Fabiano, Declan Webber
1From the Department of Psychiatry, University of Toronto, Toronto, Canada (SW, RAK); Centre for Addiction and Mental Health, Toronto, Canada (RAK); Department of Psychiatry, University of Ottawa, Ottawa, Canada (NF); and Department of Family and Community Medicine, University of Toronto, Toronto, Canada (DC).
Journal of addiction medicine
|May 17, 2024
概括
高剂量的布普伦诺芬开始,超过12毫克,没有报告过量服用或呼吸系统抑郁病例. 然而,有限的数据需要进一步研究其安全性和有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 临床研究 临床研究
背景情况:
- 高剂量布普伦诺芬 (>12毫克) 的启动是治疗阿片类药物使用障碍的新兴策略.
- 了解这种方法的安全性和有效性对于临床实践至关重要.
研究的目的:
- 审查和综合现有的关于高剂量布普伦诺芬启动的文献.
- 识别报告的结果,不良事件和当前研究的局限性.
主要方法:
- 对多个数据库 (MEDLINE,Embase,PsycINFO,Cochrane Central) 进行了全面的范围审查.
- 包括2023年2月13日之前以英语出版的研究,包括RCT,队列研究和病例报告.
主要成果:
- 分析了15项涉及580次高剂量布普伦诺芬启动的研究,这些研究涉及到各种环境.
- 没有报告致命或非致命的过量服用或呼吸系统抑郁事件.
- 常见的副作用包括恶心/吐和急性戒断;严重事件很少发生 (例如,低血压).
结论:
- 根据目前的文献,高剂量布普伦诺芬的启动似乎对过量服用和呼吸系统抑郁是安全的.
- 局限性包括不一致的不良事件报告,有限的随访和缺乏比较数据.
- 需要进行进一步的前性研究,以充分评估高剂量布普伦诺芬启动的安全性和有效性.
相关概念视频
Opioid Analgesics: Synthetic and Semisynthetic Opioids
283
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
283
Drug Abuse and Addiction: Pharmacological Phenomena
467
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
467
Analgesia and Pain Management
584
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
584
Drug Administration and Therapy Phases: Overview
451
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
451
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Opioid Receptors: Overview
749
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
749


